Anti-HIV duoCAR-T cell therapy(Lentigen Technology/University of Pittsburgh)

N/A

Report date: 2022/03/11 18:00:29

Base Information

Drug NameAnti-HIV duoCAR-T cell therapy(Lentigen Technology/University of Pittsburgh)
Drug Alias NameAnti-HIV adapative CAR-T cell therapy(Lentigen Technology/University of PittsburghLentigen Technology/University of Pittsburgh)Anti-HIV Duo chimeric antigen receptor-T cell therapy(Lentigen Technology/University of Pittsburgh)LVgp120duoCAR-T cell Therapy(Lentigen Technology/University of Pittsburgh)
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pittsburgh
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoUniversity Of California
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A